TirzeMax 20/40mg Pre-Mixed Stabilized Pen

Description

TirzeMax is an innovative research peptide that is a dual agonist of the GIP (glucose-dependent insulinotropic peptide) and GLP-1 (glucagon-like peptide-1) receptors. It is being studied in the context of type 2 diabetes, obesity, and cardiovascular disorders.

The peptide’s action is aimed at controlling blood sugar levels, improving insulin secretion, and reducing appetite, which contributes to weight management and metabolic parameters. The TirzeMax peptide is presented in a highly purified form with a purity of >99%.

The use of TirzeMax should be carried out exclusively under the supervision of the attending physician, taking into account the individual characteristics of the body and potential risks.

Composition and characteristics

Amino acid sequence and properties

• Amino acid sequence: Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{Aib}-Leu-Asp-Lys-Ile-Ala-Gln-{diacid-C20-gamma-Glu-(AEEA)2-Lys}-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
• Molecular formula: C ₂₂₅ H ₃₄₈ N ₄₈ O ₆₈
• Molecular weight: 4813.5 Da
• Purity: >99%

The main possible effects of TirzeMax (with scientific terminology)

What TirzeMax helps with / supported health aspects

• Glucose control in type 2 diabetes
• Weight loss and appetite correction
• Cardiovascular support
• Reducing inflammation in metabolic syndrome
• Potential protection of cognitive functions

Comparison with similar peptides and telomerase activators

Unlike telomerase activators such as Epitalon, TirzeMax acts through the GIP and GLP-1 receptors, influencing metabolism, appetite, and blood sugar levels. It does not stimulate telomerase and is not a classic anti-aging peptide.

Research and expert publications (scientific sources)

Studies of TirzeMax have demonstrated its high effectiveness in weight loss (up to 20% of baseline weight) and glucose control. Experiments demonstrate a reduction in muscle mass at the expense of fat mass (up to 25%), an improvement in lipid profile, and a reduction in blood pressure. The mechanism of action includes increased insulin secretion and suppression of glucagon release, slower gastric emptying, and stimulation of lipolysis.

Side effects and important warnings

• possible nausea and stomach discomfort;
• headache and mild weakness;
• changes in appetite, including decreased or temporary increase;

The use of TirzeMax depends entirely on the decisions and recommendations of the treating physician. Only a specialist determines how to inject and administer TirzeMax , based on the study objectives, the patient’s health status, and individual characteristics. Any independent changes to the dosage regimen are unacceptable and may impact the efficacy and safety of the medication.

Research data demonstrates positive results for TirzeMax in supporting weight management and metabolic parameters. However, use of the drug should only be undertaken after consultation with a physician, who will determine an individualized regimen, dosage, and frequency based on the patient’s medical condition and the objectives of the study.

Legal and ethical warning

Peptides, including TirzeMax , are research substances. Use should be strictly under medical supervision and within the context of scientific research. Use outside of a controlled context is prohibited and may be unsafe.

List of scientific literature and sources

• GLP-1 and GIP dual agonists in obesity and diabetes – NCBI
• Clinical trials of dual GIP/GLP-1 receptor agonists – NCBI